Search results
Showing 201 to 250 of 2008 results for news
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Interim process and methods statement for bringing together NICE guidance (PMG47)
This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.
NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Processes and methods for NICE-wide guidance surveillance (PMG49)
This guide describes the methods and processes that NICE follows to assess the impact of new evidence, changes to the health and care system, or other new, relevant information that has come to light after NICE guidance has published
Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
breast cancer in women with a family history of breast or ovarian cancer. [new 2013] Any explanatory notes(if applicable) Why this is...
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the cost comparison appraisal
Tell us about an interventional procedure you think should be assessed by NICE.
Our methods and processes (health technology evaluation manual)
NICE's technology appraisal and highly specialised technologies guidance manual
IMI and H2020 Grant funded projects with NICE
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
How you can use our recommendations, tools and resources: cardiovascular disease
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Physical activity: encouraging activity in the community (QS183)
This quality standard covers how local strategy, policy and planning and improvements to the built or natural physical environment such as public open spaces, workplaces and schools can encourage and support people of all ages and all abilities to be physically active and move more. It describes high-quality care in priority areas for improvement.
View quality statements for QS183Show all sections
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Science policy projects with NICE.
Partner with NICE in our research work
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
NICE's partners
and clinical indicators of late-onset infection: What is the accuracy of new or existing clinical prediction models for late-onset...
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Awaiting development Reference number: GID-TA11971 Expected publication date: TBC
consultations on guidance in progress, and future events. Subscribe to NICE news Other ways to get involved If you want to be involved...
Information and links to key resources that will help you keep your practice up-to-date.
consultations on guidance in progress, and future events. Subscribe to NICE news Other ways to get involved If you want to be involved...
Awaiting development Reference number: GID-TA11944 Expected publication date: TBC
This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]
Awaiting development Reference number: GID-TA11979 Expected publication date: TBC
In development Reference number: GID-NG10452 Expected publication date: TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]
Awaiting development Reference number: GID-TA11952 Expected publication date: TBC
Awaiting development Reference number: GID-TA11975 Expected publication date: TBC
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]
Awaiting development Reference number: GID-TA11905 Expected publication date: TBC